PMID- 21155038
OWN - NLM
STAT- MEDLINE
DCOM- 20110503
LR  - 20221207
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 52
IP  - 1
DP  - 2011 Jan
TI  - Nomogram to predict insignificant prostate cancer at radical prostatectomy in 
      Korean men: a multi-center study.
PG  - 74-80
LID - 10.3349/ymj.2011.52.1.74 [doi]
AB  - PURPOSE: Due to the availability of serum prostate specific antigen (PSA) 
      testing, the detection rate of insignificant prostate cancer (IPC) is increasing. 
      To ensure better treatment decisions, we developed a nomogram to predict the 
      probability of IPC. MATERIALS AND METHODS: The study population consisted of 
      1,471 patients who were treated at multiple institutions by radical prostatectomy 
      without neoadjuvant therapy from 1995 to 2008. We obtained nonrandom samples of n 
      = 1,031 for nomogram development, leaving n = 440 for nomogram validation. IPC 
      was defined as pathologic organ-confined disease and a tumor volume of 0.5 cc or 
      less without Gleason grade 4 or 5. Multivariate logistic regression model (MLRM) 
      coefficients were used to construct a nomogram to predict IPC from five 
      variables, including serum prostate specific antigen, clinical stage, biopsy 
      Gleason score, positive cores ratio and maximum % of tumor in any core. The 
      performance characteristics were internally validated from 200 bootstrap 
      resamples to reduce overfit bias. External validation was also performed in 
      another cohort. RESULTS: Overall, 67 (6.5%) patients had a so-called 
      "insignificant" tumor in nomogram development cohort. PSA, clinical stage, biopsy 
      Gleason score, positive core ratio and maximum % of biopsy tumor represented 
      significant predictors of the presence of IPC. The resulting nomogram had 
      excellent discrimination accuracy, with a bootstrapped concordance index of 
      0.827. CONCLUSION: Our current nomogram provides sufficiently accurate 
      information in clinical practice that may be useful to patients and clinicians 
      when various treatment options for screen-detected prostate cancer are 
      considered.
FAU - Chung, Jae Seung
AU  - Chung JS
AD  - Department of Urology, Urological Science Institute, Yonsei University College of 
      Medicine, Seoul, Korea.
FAU - Choi, Han Yong
AU  - Choi HY
FAU - Song, Hae-Ryoung
AU  - Song HR
FAU - Byun, Seok-Soo
AU  - Byun SS
FAU - Seo, Seong Il
AU  - Seo SI
FAU - Song, Cheryn
AU  - Song C
FAU - Cho, Jin Seon
AU  - Cho JS
FAU - Lee, Sang Eun
AU  - Lee SE
FAU - Ahn, Hanjong
AU  - Ahn H
FAU - Lee, Eun Sik
AU  - Lee ES
FAU - Hwang, Tae-Kon
AU  - Hwang TK
FAU - Kim, Wun-Jae
AU  - Kim WJ
FAU - Chung, Moon Kee
AU  - Chung MK
FAU - Jung, Tae Young
AU  - Jung TY
FAU - Yu, Ho Song
AU  - Yu HS
FAU - Choi, Young Deuk
AU  - Choi YD
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
SB  - IM
MH  - Aged
MH  - Asian People
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - *Nomograms
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*diagnosis/surgery
PMC - PMC3017711
COIS- The authors have no financial conflicts of interest.
EDAT- 2010/12/15 06:00
MHDA- 2011/05/04 06:00
PMCR- 2011/01/01
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/05/04 06:00 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - 201101074 [pii]
AID - 10.3349/ymj.2011.52.1.74 [doi]
PST - ppublish
SO  - Yonsei Med J. 2011 Jan;52(1):74-80. doi: 10.3349/ymj.2011.52.1.74.